Pfizer will combine its off-patent drug business with Mylan
0 Comments

Pfizer, the world’s largest drugmaker, plans to divest its off-patent drug business and combine it with generic-drug maker Mylan.

Under the terms of the agreement, which is structured as an all-stock deal, each Mylan share would be converted into one share of the new company.

Pfizer shareholders would own 57% of the combined new company and Mylan shareholders would own 43%, Mylan said. The Wall Street Journal first reported the news.

 

Pfizer will combine its off-patent drug business with Mylan

Pfizer’s Dealmaker CEO Sharpens Cancer Focus With Mylan Plan

 



3 Things to Look For in Pfizer’s Q2 Earnings Update

Mylan to combine with Pfizer’s off-patent medicines unit

Pfizer Is Said to Plan a Deal for Its Off-Patent Drugs Unit

Author

mukeshathavale.manzi@gmail.com

Leave a Reply

Your email address will not be published. Required fields are marked *